ENTERA BIO IS-0000769 (5DT) - Total Liabilities
Based on the latest financial reports, ENTERA BIO IS-0000769 (5DT) has total liabilities worth €2.89 Million EUR (≈ $3.38 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of ENTERA BIO IS-0000769 to assess how effectively this company generates cash.
ENTERA BIO IS-0000769 - Total Liabilities Trend (2021–2025)
This chart illustrates how ENTERA BIO IS-0000769's total liabilities have evolved over time, based on quarterly financial data. See shareholders equity of ENTERA BIO IS-0000769 for net asset value and shareholders' equity analysis.
ENTERA BIO IS-0000769 Competitors by Total Liabilities
The table below lists competitors of ENTERA BIO IS-0000769 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
HNA Technology Co Ltd B
SHG:900938
|
China | $1.82 Billion |
|
Doxa AB
ST:DOXA
|
Sweden | Skr2.07 Billion |
|
QPM Energy Ltd
AU:QPM
|
Australia | AU$208.69 Million |
|
Senstar Technologies Ltd
NASDAQ:SNT
|
USA | $11.45 Million |
|
Me2on Co. Ltd
KQ:201490
|
Korea | ₩22.72 Billion |
|
Stonebridge Acquisition Corp
NASDAQ:APAC
|
USA | $45.68K |
|
MFS Investment Grade Municipal Trust
NYSE:CXH
|
USA | $44.83 Million |
|
IZEA Inc
NASDAQ:IZEA
|
USA | $8.00 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down ENTERA BIO IS-0000769's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 5DT company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.94 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ENTERA BIO IS-0000769's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ENTERA BIO IS-0000769 (2021–2025)
The table below shows the annual total liabilities of ENTERA BIO IS-0000769 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €2.89 Million ≈ $3.38 Million |
+120.76% |
| 2024-12-31 | €1.31 Million ≈ $1.53 Million |
-5.00% |
| 2023-12-31 | €1.38 Million ≈ $1.61 Million |
+0.44% |
| 2022-12-31 | €1.37 Million ≈ $1.61 Million |
-59.88% |
| 2021-12-31 | €3.42 Million ≈ $4.00 Million |
-- |
About ENTERA BIO IS-0000769
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a ta… Read more